# EDGAR Filing Document

**Accession Number:** 0002058272
**File Stem:** 0001213900-25-091622
**Filing Date:** 2025-9
**Character Count:** 9317
**Document Hash:** dd5e40d11578abb16a5ae9a36c7212af
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-091622.hdr.sgml**: 20250925

**ACCESSION NUMBER**: 0001213900-25-091622

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250925

**DATE AS OF CHANGE**: 20250925

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Matinas BioPharma Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001582554
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 463011414
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89724
- **FILM NUMBER:** 251343631

**BUSINESS ADDRESS:**
- **STREET 1:** 1545 ROUTE 206 SOUTH
- **STREET 2:** SUITE 302
- **CITY:** BEDMINSTER
- **STATE:** NJ
- **ZIP:** 07921
- **BUSINESS PHONE:** 908-484-8805

**MAIL ADDRESS:**
- **STREET 1:** 1545 ROUTE 206 SOUTH
- **STREET 2:** SUITE 302
- **CITY:** BEDMINSTER
- **STATE:** NJ
- **ZIP:** 07921
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hezbay Holdings LLC
- **CENTRAL INDEX KEY:** 0002058272

**ORGANIZATION NAME:**
- **EIN:** 333115560
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 23 TAMMY ROAD
- **CITY:** SPRING VALLEY
- **STATE:** NY
- **ZIP:** 10977
- **BUSINESS PHONE:** 917-923-7072

**MAIL ADDRESS:**
- **STREET 1:** 23 TAMMY ROAD
- **CITY:** SPRING VALLEY
- **STATE:** NY
- **ZIP:** 10977

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Matinas BioPharma Holdings, Inc.**

*(Name of Issuer)*

**COMMON STOCK, $0.0001 PAR VALUE PER SHARE**

*(Title of Class of Securities)*

**576810303**

*(CUSIP Number)*

**Hezbay Holdings LLC**<br>23 Tammy Road<br>Spring Valley NY 10977<br>917-923-7072

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/25/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **576810303** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Hezbay Holdings LLC** | Name of reporting person<br>**Hezbay Holdings LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEW YORK** | Citizenship or place of organization<br>**NEW YORK** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**253841.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**253841.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**253841.00** | Aggregate amount beneficially owned by each reporting person<br>**253841.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.99%** | Percent of class represented by amount in Row (11)<br>**4.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Note to 7, 9 and 11: Based on 5,086,985 Common Shares issued and outstanding as of August 12, 2025.

Note to 12: The aggregate amount in Row 7 excludes the Common Shares purchasable pursuant to the Preferred Shares and Warrants owned by the Reporting Person which contain a contractually stipulated 4.99% ownership restriction.

| **CUSIP No.** | **576810303** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ari Kluger** | Name of reporting person<br>**Ari Kluger** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEW YORK** | Citizenship or place of organization<br>**NEW YORK** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**253841.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**253841.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**253841.00** | Aggregate amount beneficially owned by each reporting person<br>**253841.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.99%** | Percent of class represented by amount in Row (11)<br>**4.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note to 7, 9 and 11: Based on 5,086,985 Common Shares issued and outstanding as of August 12, 2025.

Note to 12: The aggregate amount in Row 7 excludes the Common Shares purchasable pursuant to the Preferred Shares and Warrants owned by the Reporting Person which contain a contractually stipulated 4.99% ownership restriction.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
COMMON STOCK, $0.0001 PAR VALUE PER SHARE

**(b) Name of Issuer:**
Matinas BioPharma Holdings, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
1545 Route 206 South, Suite 302, Bedminster, NJ, 07921

This Amendment No. 2 (the "Amendment") amends and supplements the Schedule 13D filed by the Reporting Person (as defined in Item 2 of the Schedule 13D) with the SEC (as defined in Item 5 of the Schedule 13D) on February 21, 2025 (the "Schedule 13D").  Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported on the Schedule 13D or the Schedule 13D/A filed by the Reporting Person with the SEC on April 10, 2025 ("Amendment No. 1"). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D and Amendment No. 1, as applicable. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

**Item 4. Purpose of Transaction**

Due to personal reasons, the Reporting Person has decided to withdraw from the Joint Filing Agreement dated as of February 20, 2025 and filed as Exhibit 99.4 of the Schedule 13D filed with the Securities and Exchange Agreement on February 21, 2025.  The securities owned by the Reporting Person are subjected to a 4.99 blocker provision.  Therefore, the Reporting Person is currently no longer required to file reports pursuant to Rule 13d.

**Item 5. Interest in Securities of the Issuer**

**(a)**
N/A

**(b)**
N/A

**(c)**
N/A

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Original Schedule 13D is hereby amended and supplemented to add the following:

The information set forth in Item 4 hereof is hereby incorporated by reference into this Item 6.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Hezbay Holdings LLC

**Signature:** /s/ Ari Kluger

**Name/Title:** Ari Kluger, Sole Member

**Date:** 09/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ari Kluger

**Signature:** /s/ Ari Kluger

**Name/Title:** Ari Kluger

**Date:** 09/25/2025